MedPage Today) — Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials.
The AKT inhibitor afuresertib failed to improve progression-free survival (PFS) when added to paclitaxel for patients with…
Mixed Results for Therapeutic Candidates for Platinum-Resistant Ovarian Cancer

Leave a Comment Leave a Comment
